Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months

Viking Therapeutics is down 15% year to date, despite a Wall Street average price target of $92.33 implying 207% upside over 12 months. The key catalyst is VK2735, which is in two fully enrolled phase 3 obesity trials with preliminary data expected within the next 12 months after a phase 2 result showing up to 14.7% mean weight loss at 13 weeks. The stock remains highly speculative: success in late-stage trials could drive gains, but disappointing results would likely pressure shares further.

Analysis

VKTX is a classic binary-duration setup: the stock is being priced less on current fundamentals and more on whether the market can keep extrapolating GLP-1 scarcity into a second or third entrant. The key second-order effect is that every incremental data point from late-stage obesity trials will likely be interpreted through a valuation-compression lens across the entire “next-gen obesity” basket, not just VKTX, because the market is already assuming category winners are few and scale winners are everything. That creates asymmetric upside if efficacy tolerability hold, but also an air-pocket risk if the data merely look “good” rather than clearly differentiated.

The bigger competitive question is not whether demand exists, but whether VKTX can secure a credible positioning wedge versus entrenched incumbents before payer and prescriber preference hardens. If the oral program works, it matters more than the injectable in the medium term because oral convenience is the clearest route to broadening adoption beyond the current early-adopter cohort; that would pressure the entire obesity supply chain by shifting demand toward lower-complexity, higher-volume manufacturing and away from premium injectable capacity. Conversely, disappointing readthroughs would likely hurt not only VKTX but also compress sentiment toward smaller-cap obesity peers as investors conclude that the field is converging on a duopoly.

Timing matters: the next catalyst window is measured in months, not days, but the stock can re-rate sharply on enrollment completion, trial-design updates, or any hint of labeling/tolerability advantages. The market is probably underestimating how little room there is for “close enough” in this category—if phase 3 efficacy trails the leaders by even a modest margin, the multiple can de-rate faster than the share price can reflect optionality. The contrarian view is that consensus is overpaying for headline upside while underweighting probability-adjusted dilution of enthusiasm if the readouts are merely solid instead of category-defining.

Key Decisions for Investors

• Avoid initiating a full-size long in VKTX before the next data window; if you want exposure, use a starter position only and scale on confirmed phase 3 signal, not on anticipation.
• For event-driven risk, buy VKTX call spreads 3-6 months out to express upside convexity while capping premium burn; this is preferable to outright stock given binary trial risk.
• Pair trade: long NVO vs. short VKTX into the next catalyst cycle to capture incumbent durability versus binary clinical risk; NVO benefits if obesity demand expands without meaningful share leakage.
• If you are already long VKTX, reduce position size into strength ahead of topline readouts and re-add only on confirmed efficacy/tolerability superiority; the stock’s downside on a miss likely exceeds the upside on a merely acceptable result.
• Watch for any oral-program or maintenance-study updates as tactical trading catalysts; if those programs show better convenience or durability, they can support the equity even before phase 3 data, but treat them as secondary to the core readout.